;PMID: 1632630
;source_file_652.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..47] = [t:0..47]
;1)sentence:[e:53..256] = [t:53..256]
;2)section:[e:260..282] = [t:260..282]
;3)section:[e:286..405] = [t:286..405]
;4)sentence:[e:409..571] = [t:409..571]
;5)sentence:[e:572..791] = [t:572..791]
;6)sentence:[e:792..1048] = [t:792..1048]
;7)sentence:[e:1049..1264] = [t:1049..1264]
;8)sentence:[e:1265..1606] = [t:1265..1606]
;9)sentence:[e:1608..1929] = [t:1608..1929]
;10)sentence:[e:1930..2076] = [t:1930..2076]
;11)sentence:[e:2077..2186] = [t:2077..2186]
;12)sentence:[e:2187..2532] = [t:2187..2532]
;13)sentence:[e:2534..2870] = [t:2534..2870]
;14)section:[e:2874..2918] = [t:2874..2918]

;section 0 Span:0..47
;Arch Biochem Biophys. 1992 Aug 1;296(2):366-73.
(SEC
  (FRAG (NNP:[0..4] Arch) (NNP:[5..12] Biochem) (NNP:[13..20] Biophys)
        (.:[20..21] .) (CD:[22..26] 1992) (NNP:[27..30] Aug) (CD:[31..36] 1;296)
        (-LRB-:[36..37] -LRB-) (CD:[37..38] 2) (-RRB-:[38..39] -RRB-)
        (::[39..40] :) (CD:[40..46] 366-73) (.:[46..47] .)))

;sentence 1 Span:53..256
;Hydroxylation of 5 alpha-androstane-3 beta,17 beta-diol by rat prostate 
;microsomes: potent inhibition by imidazole-type antimycotic drugs and lack of
; inhibition by steroid 5 alpha-reductase inhibitors.
;[70..108]:substance:"5 alpha-androstane-3 beta,17 beta-diol"
;[159..168]:substance:"imidazole"
;[174..191]:substance:"antimycotic drugs"
;[219..244]:substance:"steroid 5 alpha-reductase"
;[245..255]:substance:"inhibitors"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[53..66] Hydroxylation))
      (PP (IN:[67..69] of)
        (NP (CD:[70..71] 5) (NN:[72..90] alpha-androstane-3)
            (NN:[91..98] beta,17) (NN:[99..108] beta-diol)))
      (PP (IN:[109..111] by)
        (NP (NN:[112..115] rat) (NN:[116..124] prostate)
            (NNS:[126..136] microsomes))))
    (::[136..137] :)
    (NP
      (NP
        (NP (JJ:[138..144] potent) (NN:[145..155] inhibition))
        (PP (IN:[156..158] by)
          (NP
            (NML (NN:[159..168] imidazole) (HYPH:[168..169] -)
                 (NN:[169..173] type))
             (JJ:[174..185] antimycotic) (NNS:[186..191] drugs))))
      (CC:[192..195] and)
      (NP
        (NP (NN:[196..200] lack))
        (PP (IN:[201..203] of)
          (NP
            (NP (NN:[205..215] inhibition))
            (PP (IN:[216..218] by)
              (NP
                
                (NML (NN:[219..226] steroid) (CD:[227..228] 5))
                (NN:[229..244] alpha-reductase)
                (NNS:[245..255] inhibitors)))))))
    (.:[255..256] .)))

;section 2 Span:260..282
;Gemzik B, Parkinson A.
(SEC
  (FRAG (NNP:[260..266] Gemzik) (NNP:[267..268] B) (,:[268..269] ,)
        (NNP:[270..279] Parkinson) (NNP:[280..281] A) (.:[281..282] .)))

;section 3 Span:286..405
;Department of Pharmacology, Toxicology, and Therapeutics, University of
;Kansas  Medical Center, Kansas City 66160-7417.
(SEC
  (FRAG (NNP:[286..296] Department) (IN:[297..299] of)
        (NNP:[300..312] Pharmacology) (,:[312..313] ,)
        (NNP:[314..324] Toxicology) (,:[324..325] ,) (CC:[326..329] and)
        (NNP:[330..342] Therapeutics) (,:[342..343] ,)
        (NNP:[344..354] University) (IN:[355..357] of) (NNP:[358..364] Kansas)
        (NNP:[366..373] Medical) (NNP:[374..380] Center) (,:[380..381] ,)
        (NNP:[382..388] Kansas) (NNP:[389..393] City) (CD:[394..399] 66160)
        (::[399..400] -) (CD:[400..404] 7417) (.:[404..405] .)))

;sentence 4 Span:409..571
;5 alpha-Dihydrotestosterone, the principal androgen mediating prostate growth
; and function in the rat, is formed from testosterone by steroid 5 
;alpha-reductase.
;[409..436]:substance:"5 alpha-Dihydrotestosterone"
;[452..460]:substance:"androgen"
;[528..540]:substance:"testosterone"
;[544..570]:substance:"steroid 5  alpha-reductase"
(SENT
  (S
    (NP-SBJ-2
      (NP (CD:[409..410] 5) (NN:[411..436] alpha-Dihydrotestosterone))
      (,:[436..437] ,)
      (NP
        (NP (DT:[438..441] the) (JJ:[442..451] principal)
            (NN:[452..460] androgen))
        (VP (VBG:[461..470] mediating)
          (NP
            (NP
              (NML-1 (NN:[471..479] prostate))
              (NN:[480..486] growth))
            (CC:[488..491] and)
            (NP
              (NML-1 (-NONE-:[491..491] *P*))
              (NN:[492..500] function)))
          (PP-LOC (IN:[501..503] in)
            (NP (DT:[504..507] the) (NN:[508..511] rat))))))
    (,:[511..512] ,)
    (VP (VBZ:[513..515] is)
      (VP (VBN:[516..522] formed)
        (NP-2 (-NONE-:[522..522] *))
        (NP (IN:[523..527] from)
          (NP (NN:[528..540] testosterone)))
        (PP (IN:[541..543] by)
          (NP-LGS
            (NML (NN:[544..551] steroid) (CD:[552..553] 5))
            (NN:[555..570] alpha-reductase)))))
    (.:[570..571] .)))

;sentence 5 Span:572..791
;The inactivation of 5 alpha-dihydrotestosterone involves  reversible
;reduction to 5 alpha-androstane-3 beta,17 beta-diol by 3  beta-hydroxysteroid
;oxidoreductase followed by 6 alpha-, 7 alpha-, or 7  beta-hydroxylation.
;[592..619]:substance:"5 alpha-dihydrotestosterone"
;[654..692]:substance:"5 alpha-androstane-3 beta,17 beta-diol"
;[696..733]:substance:"3  beta-hydroxysteroid oxidoreductase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[572..575] The) (NN:[576..588] inactivation))
      (PP (IN:[589..591] of)
        (NP (CD:[592..593] 5) (NN:[594..619] alpha-dihydrotestosterone))))
    (VP (VBZ:[620..628] involves)
      (NP
        (NP (JJ:[630..640] reversible) (NN:[641..650] reduction))
        (PP (TO:[651..653] to)
          (NP (CD:[654..655] 5) (NN:[656..674] alpha-androstane-3)
              (NN:[675..682] beta,17) (NN:[683..692] beta-diol)))
        (PP (IN:[693..695] by)
          (NP (CD:[696..697] 3) (NN:[699..718] beta-hydroxysteroid)
              (NN:[719..733] oxidoreductase)))
        (VP (VBN:[734..742] followed)
          (NP (-NONE-:[742..742] *))
          (PP (IN:[743..745] by)
            (NP-LGS
              (NP
                (NML (CD:[746..747] 6) (SYM:[748..753] alpha))
                (HYPH:[753..754] -)
                (NML-1 (-NONE-:[754..754] *P*)))
              (,:[754..755] ,)
              (NP
                (NML (CD:[756..757] 7) (SYM:[758..763] alpha))
                (HYPH:[763..764] -)
                (NML-1 (-NONE-:[764..764] *P*)))
              (,:[764..765] ,) (CC:[766..768] or)
              (NP
                (NML (CD:[769..770] 7) (SYM:[772..776] beta))
                (HYPH:[776..777] -)
                (NML-1 (NN:[777..790] hydroxylation))))))))
    (.:[790..791] .)))

;sentence 6 Span:792..1048
;5 alpha-Androstane-3 beta,17 beta-diol hydroxylation  represents the ultimate
;inactivation step of dihydrotestosterone in rat prostate  and is apparently
;catalyzed by a single, high-affinity (Km approximately 0.5  microM)
;microsomal cytochrome P450 enzyme.
;[792..830]:substance:"5 alpha-Androstane-3 beta,17 beta-diol"
;[891..910]:substance:"dihydrotestosterone"
;[984..986]:quantitative-name:"Km"
;[1001..1004]:quantitative-value:"0.5"
;[1006..1012]:quantitative-units:"microM"
;[1025..1047]:cyp450:"cytochrome P450 enzyme"
(SENT
  (S
    (NP-SBJ-1
      (NML (CD:[792..793] 5) (NN:[794..812] alpha-Androstane-3)
           (NN:[813..820] beta,17) (NN:[821..830] beta-diol))
      (NN:[831..844] hydroxylation))
    (VP
      (VP (VBZ:[846..856] represents)
        (NP
          (NP (DT:[857..860] the) (JJ:[861..869] ultimate)
              (NN:[870..882] inactivation) (NN:[883..887] step))
          (PP (IN:[888..890] of)
            (NP (NN:[891..910] dihydrotestosterone)))
          (PP-LOC (IN:[911..913] in)
            (NP (NN:[914..917] rat) (NN:[918..926] prostate)))))
      (CC:[928..931] and)
      (VP (VBZ:[932..934] is)
        (ADVP (RB:[935..945] apparently))
        (VP (VBN:[946..955] catalyzed)
          (NP-1 (-NONE-:[955..955] *))
          (PP (IN:[956..958] by)
            (NP-LGS (DT:[959..960] a) (JJ:[961..967] single) (,:[967..968] ,)
              (ADJP
                (ADJP (JJ:[969..973] high) (HYPH:[973..974] -)
                      (NN:[974..982] affinity))
                (PRN (-LRB-:[983..984] -LRB-)
                  (S
                    (NP-SBJ (NN:[984..986] Km))
                    (NP-PRD
                      (QP (RB:[987..1000] approximately) (CD:[1001..1004] 0.5))
                      (NN:[1006..1012] microM)))
                  (-RRB-:[1012..1013] -RRB-)))
              (JJ:[1014..1024] microsomal)
              
              (NML (NN:[1025..1035] cytochrome) (NN:[1036..1040] P450))
              (NN:[1041..1047] enzyme))))))
    (.:[1047..1048] .)))

;sentence 7 Span:1049..1264
;The present studies were designed to  determine if 5 alpha-androstane-3
;beta,17 beta-diol hydroxylation by rat  prostate microsomes is inhibited by
;agents that are known inhibitors of  androgen-metabolizing enzymes.
;[1100..1138]:substance:"5 alpha-androstane-3 beta,17 beta-diol"
;[1197..1203]:substance:"agents"
;[1219..1229]:substance:"inhibitors"
;[1234..1263]:substance:"androgen-metabolizing enzymes"
(SENT
  (S
    (NP-SBJ-3 (DT:[1049..1052] The) (JJ:[1053..1060] present)
              (NNS:[1061..1068] studies))
    (VP (VBD:[1069..1073] were)
      (VP (VBN:[1074..1082] designed)
        (S
          (NP-SBJ-3 (-NONE-:[1082..1082] *))
          (VP (TO:[1083..1085] to)
            (VP (VB:[1087..1096] determine)
              (SBAR (IN:[1097..1099] if)
                (S
                  (NP-SBJ-2
                    (NP
                      (NML (CD:[1100..1101] 5)
                           (NN:[1102..1120] alpha-androstane-3)
                           (NN:[1121..1128] beta,17) (NN:[1129..1138] beta-diol))
                      (NN:[1139..1152] hydroxylation))
                    (PP (IN:[1153..1155] by)
                      (NP (NN:[1156..1159] rat) (NN:[1161..1169] prostate)
                          (NNS:[1170..1180] microsomes))))
                  (VP (VBZ:[1181..1183] is)
                    (VP (VBN:[1184..1193] inhibited)
                      (NP-2 (-NONE-:[1193..1193] *))
                      (PP (IN:[1194..1196] by)
                        (NP-LGS
                          (NP (NNS:[1197..1203] agents))
                          (SBAR
                            (WHNP-1 (WDT:[1204..1208] that))
                            (S
                              (NP-SBJ-1 (-NONE-:[1208..1208] *T*))
                              (VP (VBP:[1209..1212] are)
                                (NP-PRD
                                  (NP (VBN:[1213..1218] known)
                                      (NNS:[1219..1229] inhibitors))
                                  (PP (IN:[1230..1232] of)
                                    (NP
                                      (ADJP (NN:[1234..1242] androgen)
                                            (HYPH:[1242..1243] -)
                                            (VBG:[1243..1255] metabolizing))
                                      (NNS:[1256..1263] enzymes))))))))))))))))))
    (.:[1263..1264] .)))

;sentence 8 Span:1265..1606
;Inhibitors of steroid 5 alpha-reductase  (4-azasteroid analogs; 10 microM) or
;inhibitors of 3 beta-hydroxysteroid  oxidoreductase (trilostane, azastene,
;and cyanoketone; 10 microM) had no  appreciable effect on the 6 alpha-, 7
;alpha-, or 7 beta-hydroxylation of 5  alpha-androstane-3 beta,17 beta-diol
;(10 microM) by rat prostate microsomes.
;[1265..1275]:substance:"Inhibitors"
;[1279..1304]:substance:"steroid 5 alpha-reductase"
;[1307..1327]:substance:"4-azasteroid analogs"
;[1329..1331]:quantitative-value:"10"
;[1332..1338]:quantitative-units:"microM"
;[1343..1353]:substance:"inhibitors"
;[1357..1394]:substance:"3 beta-hydroxysteroid  oxidoreductase"
;[1396..1406]:substance:"trilostane"
;[1408..1416]:substance:"azastene"
;[1422..1433]:substance:"cyanoketone"
;[1435..1437]:quantitative-value:"10"
;[1438..1444]:quantitative-units:"microM"
;[1527..1566]:substance:"5  alpha-androstane-3 beta,17 beta-diol"
;[1568..1570]:quantitative-value:"10"
;[1571..1577]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NNS:[1265..1275] Inhibitors))
        (PP (IN:[1276..1278] of)
          (NP
            (NML (NN:[1279..1286] steroid) (CD:[1287..1288] 5))
            (NN:[1289..1304] alpha-reductase)))
        (PRN (-LRB-:[1306..1307] -LRB-)
          (NP
            (NP (NN:[1307..1319] 4-azasteroid) (NNS:[1320..1327] analogs))
            (::[1327..1328] ;)
            (NP (CD:[1329..1331] 10) (NN:[1332..1338] microM)))
          (-RRB-:[1338..1339] -RRB-)))
      (CC:[1340..1342] or)
      (NP
        (NP (NNS:[1343..1353] inhibitors))
        (PP (IN:[1354..1356] of)
          (NP (CD:[1357..1358] 3) (NN:[1359..1378] beta-hydroxysteroid)
              (NN:[1380..1394] oxidoreductase)))
        (PRN (-LRB-:[1395..1396] -LRB-)
          (NP
            (NP (NN:[1396..1406] trilostane) (,:[1406..1407] ,)
                (NN:[1408..1416] azastene) (,:[1416..1417] ,)
                (CC:[1418..1421] and) (NN:[1422..1433] cyanoketone))
            (::[1433..1434] ;)
            (NP (CD:[1435..1437] 10) (NN:[1438..1444] microM)))
          (-RRB-:[1444..1445] -RRB-))))
    (VP (VBD:[1446..1449] had)
      (NP
        (NP (DT:[1450..1452] no) (JJ:[1454..1465] appreciable)
            (NN:[1466..1472] effect))
        (PP (IN:[1473..1475] on)
          (NP
            (NP (DT:[1476..1479] the)
              (NML
                (NML
                  (NML (CD:[1480..1481] 6) (SYM:[1482..1487] alpha))
                  (HYPH:[1487..1488] -)
                  (NML-1 (-NONE-:[1488..1488] *P*)))
                (,:[1488..1489] ,)
                (NML
                  (NML (CD:[1490..1491] 7) (SYM:[1492..1497] alpha))
                  (HYPH:[1497..1498] -)
                  (NML-1 (-NONE-:[1498..1498] *P*)))
                (,:[1498..1499] ,) (CC:[1500..1502] or)
                (NML
                  (NML (CD:[1503..1504] 7) (SYM:[1505..1509] beta))
                  (HYPH:[1509..1510] -)
                  (NML-1 (NN:[1510..1523] hydroxylation)))))
            (PP (IN:[1524..1526] of)
              (NP
                (NP (CD:[1527..1528] 5) (NN:[1530..1548] alpha-androstane-3)
                    (NN:[1549..1556] beta,17) (NN:[1557..1566] beta-diol))
                (PRN (-LRB-:[1567..1568] -LRB-)
                  (NP (CD:[1568..1570] 10) (NN:[1571..1577] microM))
                  (-RRB-:[1577..1578] -RRB-))))
            (PP (IN:[1579..1581] by)
              (NP (NN:[1582..1585] rat) (NN:[1586..1594] prostate)
                  (NNS:[1595..1605] microsomes)))))))
    (.:[1605..1606] .)))

;sentence 9 Span:1608..1929
;Imidazole-type antimycotic drugs (ketoconazole, clotrimazole, and miconazole;
; 0.1-10 microM) all markedly inhibited 5 alpha-androstane-3 beta,17 beta-diol
; hydroxylation in a concentration-dependent manner, whereas triazole-type 
;antimycotic drugs (fluconazole and itraconazole; 0.1-10 microM) had no 
;inhibitory effect.
;[1608..1617]:substance:"Imidazole"
;[1635..1640]:substance:"drugs"
;[1642..1654]:substance:"ketoconazole"
;[1656..1668]:substance:"clotrimazole"
;[1674..1684]:substance:"miconazole"
;[1687..1693]:quantitative-value:"0.1-10"
;[1694..1700]:quantitative-units:"microM"
;[1725..1763]:substance:"5 alpha-androstane-3 beta,17 beta-diol"
;[1824..1832]:substance:"triazole"
;[1839..1856]:substance:"antimycotic drugs"
;[1858..1869]:substance:"fluconazole"
;[1874..1886]:substance:"itraconazole"
;[1888..1894]:quantitative-value:"0.1-10"
;[1895..1901]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (NN:[1608..1617] Imidazole) (HYPH:[1617..1618] -)
             (NN:[1618..1622] type))
        (JJ:[1623..1634] antimycotic) (NNS:[1635..1640] drugs))
      (PRN (-LRB-:[1641..1642] -LRB-)
        (NP
          (NP (NN:[1642..1654] ketoconazole) (,:[1654..1655] ,)
              (NN:[1656..1668] clotrimazole) (,:[1668..1669] ,)
              (CC:[1670..1673] and) (NN:[1674..1684] miconazole))
          (::[1684..1685] ;)
          (NP
            (QP (CD:[1687..1690] 0.1) (HYPH:[1690..1691] -) (CD:[1691..1693] 10))
            (NN:[1694..1700] microM)))
        (-RRB-:[1700..1701] -RRB-)))
    (DT:[1702..1705] all)
    (ADVP (RB:[1706..1714] markedly))
    (VP (VBD:[1715..1724] inhibited)
      (NP
        (NML (CD:[1725..1726] 5) (NN:[1727..1745] alpha-androstane-3)
             (NN:[1746..1753] beta,17) (NN:[1754..1763] beta-diol))
        (NN:[1765..1778] hydroxylation))
      (PP-MNR (IN:[1779..1781] in)
        (NP (DT:[1782..1783] a)
          (ADJP (NN:[1784..1797] concentration) (HYPH:[1797..1798] -)
                (JJ:[1798..1807] dependent))
          (NN:[1808..1814] manner)))
      (,:[1814..1815] ,)
      (SBAR-ADV (IN:[1816..1823] whereas)
        (S
          (NP-SBJ
            (NP
              (NML (NN:[1824..1832] triazole) (HYPH:[1832..1833] -)
                   (NN:[1833..1837] type))
               (JJ:[1839..1850] antimycotic) (NNS:[1851..1856] drugs))
            (PRN (-LRB-:[1857..1858] -LRB-)
              (NP
                (NP (NN:[1858..1869] fluconazole) (CC:[1870..1873] and)
                    (NN:[1874..1886] itraconazole))
                (::[1886..1887] ;)
                (NP
                  (QP (CD:[1888..1891] 0.1) (HYPH:[1891..1892] -)
                      (CD:[1892..1894] 10))
                  (NN:[1895..1901] microM)))
              (-RRB-:[1901..1902] -RRB-)))
          (VP (VBD:[1903..1906] had)
            (NP (DT:[1907..1909] no) (JJ:[1911..1921] inhibitory)
                (NN:[1922..1928] effect))))))
    (.:[1928..1929] .)))

;sentence 10 Span:1930..2076
;The rank order of inhibitory potency of the imidazole-type  antimycotic drugs
;was miconazole greater than clotrimazole greater than  ketoconazole.
;[1974..1983]:substance:"imidazole"
;[2002..2007]:substance:"drugs"
;[2012..2022]:substance:"miconazole"
;[2036..2048]:substance:"clotrimazole"
;[2063..2075]:substance:"ketoconazole"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1930..1933] The) (NN:[1934..1938] rank) (NN:[1939..1944] order))
      (PP (IN:[1945..1947] of)
        (NP (JJ:[1948..1958] inhibitory) (NN:[1959..1966] potency)))
      (PP (IN:[1967..1969] of)
        (NP (DT:[1970..1973] the)
          (NML (NN:[1974..1983] imidazole) (HYPH:[1983..1984] -)
               (NN:[1984..1988] type))
          (JJ:[1990..2001] antimycotic) (NNS:[2002..2007] drugs))))
    (VP (VBD:[2008..2011] was)
      (NP-PRD
        (NP (NN:[2012..2022] miconazole))
        (ADJP (JJR:[2023..2030] greater)
          (PP (IN:[2031..2035] than)
            (NP
              (NP (NN:[2036..2048] clotrimazole))
              (ADJP (JJR:[2049..2056] greater)
                (PP (IN:[2057..2061] than)
                  (NP (NN:[2063..2075] ketoconazole)))))))))
    (.:[2075..2076] .)))

;sentence 11 Span:2077..2186
;In the case of clotrimazole, the inhibition was shown to be  competitive in
;nature, with a Ki of 0.03 microM.
;[2092..2104]:substance:"clotrimazole"
;[2168..2170]:quantitative-name:"Ki"
;[2174..2178]:quantitative-value:"0.03"
;[2179..2185]:quantitative-units:"microM"
(SENT
  (S
    (PP-LOC (IN:[2077..2079] In)
      (NP
        (NP (DT:[2080..2083] the) (NN:[2084..2088] case))
        (PP (IN:[2089..2091] of)
          (NP (NN:[2092..2104] clotrimazole)))))
    (,:[2104..2105] ,)
    (NP-SBJ-1 (DT:[2106..2109] the) (NN:[2110..2120] inhibition))
    (VP (VBD:[2121..2124] was)
      (VP (VBN:[2125..2130] shown)
        (S
          (NP-SBJ-1 (-NONE-:[2130..2130] *))
          (VP (TO:[2131..2133] to)
            (VP (VB:[2134..2136] be)
              (ADJP-PRD (JJ:[2138..2149] competitive)
                (PP (IN:[2150..2152] in)
                  (NP (NN:[2153..2159] nature))))
              (,:[2159..2160] ,)
              (PP (IN:[2161..2165] with)
                (NP
                  (NP (DT:[2166..2167] a) (NN:[2168..2170] Ki))
                  (PP (IN:[2171..2173] of)
                    (NP (CD:[2174..2178] 0.03) (NN:[2179..2185] microM))))))))))
    (.:[2185..2186] .)))

;sentence 12 Span:2187..2532
;The imidazole-type antimycotic  drugs inhibited all three pathways of 5
;alpha-androstane-3 beta,17 beta-diol  hydroxylation to the same extent, which
;provides further evidence that, in rat  prostate microsomes, a single
;cytochrome P450 enzyme catalyzes the 6 alpha-, 7  alpha-, and 7
;beta-hydroxylation of 5 alpha-androstane-3 beta,17 beta-diol.
;[2191..2200]:substance:"imidazole"
;[2206..2224]:substance:"antimycotic  drugs"
;[2257..2295]:substance:"5 alpha-androstane-3 beta,17 beta-diol"
;[2407..2429]:cyp450:"cytochrome P450 enzyme"
;[2493..2531]:substance:"5 alpha-androstane-3 beta,17 beta-diol"
(SENT
  (S
    (NP-SBJ (DT:[2187..2190] The)
      (NML (NN:[2191..2200] imidazole) (HYPH:[2200..2201] -)
           (NN:[2201..2205] type))
       (JJ:[2206..2217] antimycotic) (NNS:[2219..2224] drugs))
    (VP (VBD:[2225..2234] inhibited)
      (NP
        (NP
          (QP (DT:[2235..2238] all) (CD:[2239..2244] three))
          (NNS:[2245..2253] pathways))
        (PP (IN:[2254..2256] of)
          (NP
            (NML (CD:[2257..2258] 5) (NN:[2259..2277] alpha-androstane-3)
                 (NN:[2278..2285] beta,17) (NN:[2286..2295] beta-diol))
            (NN:[2297..2310] hydroxylation))))
      (PP-EXT (TO:[2311..2313] to)
        (NP (DT:[2314..2317] the) (JJ:[2318..2322] same)
            (NN:[2323..2329] extent)))
      (,:[2329..2330] ,)
      (SBAR-ADV
        (WHNP-2 (WDT:[2331..2336] which))
        (S
          (NP-SBJ-2 (-NONE-:[2336..2336] *T*))
          (VP (VBZ:[2337..2345] provides)
            (NP (JJ:[2346..2353] further) (NN:[2354..2362] evidence)
              (SBAR (IN:[2363..2367] that) (,:[2367..2368] ,)
                (S
                  (PP-LOC (IN:[2369..2371] in)
                    (NP (NN:[2372..2375] rat) (NN:[2377..2385] prostate)
                        (NNS:[2386..2396] microsomes)))
                  (,:[2396..2397] ,)
                  (NP-SBJ (DT:[2398..2399] a) (JJ:[2400..2406] single)
                    
                    (NML (NN:[2407..2417] cytochrome) (NN:[2418..2422] P450))
                    (NN:[2423..2429] enzyme))
                  (VP (VBZ:[2430..2439] catalyzes)
                    (NP
                      (NP (DT:[2440..2443] the)
                        (NML
                          (NML
                            (NML (CD:[2444..2445] 6) (SYM:[2446..2451] alpha))
                            (HYPH:[2451..2452] -)
                            (NML-1 (-NONE-:[2452..2452] *P*)))
                          (,:[2452..2453] ,)
                          (NML
                            (NML (CD:[2454..2455] 7) (SYM:[2457..2462] alpha))
                            (HYPH:[2462..2463] -)
                            (NML-1 (-NONE-:[2463..2463] *P*)))
                          (,:[2463..2464] ,) (CC:[2465..2468] and)
                          (NML
                            (NML (CD:[2469..2470] 7) (SYM:[2471..2475] beta))
                            (HYPH:[2475..2476] -)
                            (NML-1 (NN:[2476..2489] hydroxylation)))))
                      (PP (IN:[2490..2492] of)
                        (NP (CD:[2493..2494] 5)
                            (NN:[2495..2513] alpha-androstane-3)
                            (NN:[2514..2521] beta,17)
                            (NN:[2522..2531] beta-diol))))))))))))
    (.:[2531..2532] .)))

;sentence 13 Span:2534..2870
;These studies demonstrate that certain imidazole-type compounds are potent, 
;competitive inhibitors of 5 alpha-androstane-3 beta,17 beta-diol
;hydroxylation  by rat prostate microsomes, which is consistent with the
;effect of these  antimycotic drugs on cytochrome P450 enzymes involved in the
;metabolism of other  androgens and steroids.
;[2573..2582]:substance:"imidazole"
;[2588..2597]:substance:"compounds"
;[2623..2633]:substance:"inhibitors"
;[2637..2675]:substance:"5 alpha-androstane-3 beta,17 beta-diol"
;[2765..2782]:substance:"antimycotic drugs"
;[2786..2809]:cyp450:"cytochrome P450 enzymes"
;[2847..2856]:substance:"androgens"
;[2861..2869]:substance:"steroids"
(SENT
  (S
    (NP-SBJ (DT:[2534..2539] These) (NNS:[2540..2547] studies))
    (VP (VBP:[2548..2559] demonstrate)
      (SBAR (IN:[2560..2564] that)
        (S
          (NP-SBJ (JJ:[2565..2572] certain)
            (NML (NN:[2573..2582] imidazole) (HYPH:[2582..2583] -)
                 (NN:[2583..2587] type))
            (NNS:[2588..2597] compounds))
          (VP (VBP:[2598..2601] are)
            (NP-PRD
              (NP (JJ:[2602..2608] potent) (,:[2608..2609] ,)
                  (JJ:[2611..2622] competitive) (NNS:[2623..2633] inhibitors))
              (PP (IN:[2634..2636] of)
                (NP
                  (NP
                    (NML (CD:[2637..2638] 5)
                         (NN:[2639..2657] alpha-androstane-3)
                         (NN:[2658..2665] beta,17) (NN:[2666..2675] beta-diol))
                    (NN:[2676..2689] hydroxylation))
                  (PP (IN:[2691..2693] by)
                    (NP (NN:[2694..2697] rat) (NN:[2698..2706] prostate)
                        (NNS:[2707..2717] microsomes))))))
            (,:[2717..2718] ,)
            (SBAR-ADV
              (WHNP-2 (WDT:[2719..2724] which))
              (S
                (NP-SBJ-2 (-NONE-:[2724..2724] *T*))
                (VP (VBZ:[2725..2727] is)
                  (ADJP-PRD (JJ:[2728..2738] consistent)
                    (PP (IN:[2739..2743] with)
                      (NP
                        (NP (DT:[2744..2747] the) (NN:[2748..2754] effect))
                        (PP (IN:[2755..2757] of)
                          (NP (DT:[2758..2763] these)
                             (JJ:[2765..2776] antimycotic)
                             (NNS:[2777..2782] drugs)))
                        (PP (IN:[2783..2785] on)
                          (NP
                            (NP
                              (NML (NN:[2786..2796] cytochrome)
                                   (NN:[2797..2801] P450))
                              (NNS:[2802..2809] enzymes))
                            (VP (VBN:[2810..2818] involved)
                              (NP (-NONE-:[2818..2818] *))
                              (PP-CLR (IN:[2819..2821] in)
                                (NP
                                  (NP (DT:[2822..2825] the)
                                      (NN:[2826..2836] metabolism))
                                  (PP (IN:[2837..2839] of)
                                    (NP
                                      (NP
                                        (ADJP-1 (JJ:[2840..2845] other))
                                        (NNS:[2847..2856] androgens))
                                      (CC:[2857..2860] and)
                                      (NP
                                        (ADJP-1 (-NONE-:[2860..2860] *P*))
                                        (NNS:[2861..2869] steroids)))))))))))))))))))
    (.:[2869..2870] .)))

;section 14 Span:2874..2918
;PMID: 1632630 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2874..2878] PMID) (::[2878..2879] :) (CD:[2880..2887] 1632630)
        (NN:[2888..2889] -LSB-) (NNP:[2889..2895] PubMed) (::[2896..2897] -)
        (NN:[2898..2905] indexed) (IN:[2906..2909] for)
        (NNP:[2910..2918] MEDLINE-RSB-)))
